GDMT Linked to Lower Mortality in LVAD Recipients

This international registry provides the largest real-world signal that neurohormonal therapy, even a single agent, is associated with survival benefit after durable LVAD implantation.

guideline-directed medical therapybeta-blockersACE inhibitorsARBsmineralocorticoid receptor antagonistsleft ventricular assist deviceheart failureventricular arrhythmiaretrospective cohortVT-LVAD Consortium Cardiology / Anticoagulation

Background Information

GDMT boosts survival in LVAD patients, but why so underused?

Guideline-directed medical therapy (GDMT) is recommended for left ventricular assist device (LVAD) recipients, yet its real-world impact needs clarity. The study showed that GDMT was associated with improved survival in LVAD patients, with triple therapy reducing all-cause mortality by 49% and also lowering late ventricular arrhythmias. While GDMT improves outcomes, only 30% of patients received all recommended therapies, indicating a need for better implementation in LVAD care. GDMT significantly enhances survival in LVAD patients, but uptake remains low.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Cherbi M, Delmas C, Gautier P, Benali K, Bode K, Efimova E, Dashkevich A, Liang J, Larson J, Mondesert B, Boulet J, Noly PE, Picard F, Pasquié JL, Gourraud JB, Ninni S, Jesel L, Sebestyen A, Para M, Deharo JC, Anselme F, Champ-Rigot L, M'Rabet S, Pierre B, Eschalier R, Echivard M, Martin AC, Lellouche N, Pozzi M, Groussin P, Flecher E, Galand V, Martins R

Citation: Cherbi M, Delmas C, Gautier P, et al. Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study. ESC heart failure. 2026;13(4). doi:10.1093/eschf/xvag174

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →